4DMedical rallies after regulatory approval, reshaping imaging reach
The 4DMedical share price surged on Tuesday as a number of positive developments including the rapid pace of commercial and regulatory progress highlighted how quickly the company is moving forward.
4DMedical Limited (ASX: 4DX)
on 15 December announced that it has received Canadian regulatory approval for CT:VQ which is the world’s first and only non-contrast C-T based ventilation-perfusion imaging solution.
This approval will lead to expansion of 4DMedical’s footprint in North America and enables immediate commercial deployment of CT:VQ across Canada through the company’s strategic partnership with Philips.
4DMedical also announced that it has secured $30.2 million through a fully underwritten options exercise which has made the company’s balance sheet much stronger as following this funding, the company reported a pro forma cash balance of $63.7 million as at 30 September.
On 10 December, the company announced that the University of Miami commenced clinical use of CT:VQ which makes it the second US academic medical centre after Stanford to adopt the technology and the company signed a new two-year agreement with Lahey Hospital and Medical Centre which reinforces early commercial traction in the US market.
On 3 December, the company announced a major expansion of its distribution agreement under which Philips will add CT:VQ to its North American product catalogue and this includes a minimum customer order commitment of approximately US$10 million over the next two years.
The AstraZeneca partnership also expanded to six hospitals which collectively cover around 48,000 CT scans annually for a lung health screening program in Brazil.
Operating revenue for Q1 FY26 was $1.4 million and gross margins were above 90% which reflects strong revenue quality at an early stage.
4DMedical is currently delivering its SaaS products across 409 sites globally which represents a 50.9% year-on-year increase and the company produced more than 74,345 scans in Q1 FY26 which represents a 105.6% year-on-year rise.
Management is currently focused on scaling CT:VQ adoption while expanding partnerships which keeps the company well positioned for revenue growth through FY26 and beyond.
(Source: Company Announcements)
Get Your Free Report on Top 5 ASX Stocks on WhatsApp
Instant Access. No Credit Card Required.
Receive on WhatsApp
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialASX Stock Research & Recommendations — 7‑day free trial
Independent, analyst‑driven insights.
- Stock of the week report
- Daily Analysis Report
- No credit card required
Get Your FREE Report
Discover the Top ASX Stocks to Invest In 2026!
Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Article
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
